BioCentury | Jul 21, 2008
Company News

Bellus Health, Innodia deal

...acquired Innodia for C$1.3 million (US$1.3 million) in stock. The purchase includes the assumption of Innodia's...
...II diabetes, with interim data expected in 1H09. Bellus Health Inc. (TSX:BLU; NASDAQ:BLUS), Laval, Quebec Innodia Inc....
BioCentury | Mar 26, 2007
Product Development

Targeting obesity

...blocks NPY5 receptor (4) . The mechanisms for Manhattan Pharmaceuticals' natural hormone oleoyl-esterone and Innodia's...
BioCentury | Mar 26, 2007
Product Development

Metabolic Milestones

...up the body's energy expenditure without a concomitant increase in appetite. In that camp is Innodia Inc....
...of fat into triglycerides. While Adyvia was initially developed for Type II diabetes, Vezeau said Innodia...
...and lipid profile. While the exact mechanism of Adyvia has yet to be fully elucidated, Innodia...
BioCentury | Mar 26, 2007
Product Development

Reaching proof of concept

...data 07 (A) GlaxoSmithKline/ Kissei Sergliflozin (869682, KGT-1251) Sodium-glucose cotransporter 2 (SGLT2) inhibitor SGLT2 NA Innodia...
BioCentury | Mar 12, 2007
Company News

Innodia scientific advisory board update

Innodia Inc. , Laval, Quebec Business: Endocrine Appointed: David York, director of the Center for Advanced Nutrition at Utah State University; and Robert Zamboni, former VP at Merck & Co. Inc. WIR Staff...
BioCentury | Dec 11, 2006
Clinical News

Adyvia: Phase IIa started

...Innodia began a double-blind, placebo-controlled, Canadian Phase IIa trial in 100 patients. Innodia Inc. , Laval, Quebec...
BioCentury | Dec 4, 2006
Company News

Innodia management update

Innodia Inc. , Laval, Quebec Business: Endocrine Hired: Nigel Levens as CSO, formerly head of biology at Biovitrum AG WIR Staff...
BioCentury | Nov 22, 2006
Company News

Innodia names Levens CSO

...Diabetes and obesity company Innodia (Laval, Quebec) hired Nigel Levens as CSO, a newly created position...
BioCentury | Jul 18, 2005
Emerging Company Profile

Innodia: Surrounding diabetes

...In a slight twist on the typical NRDO business model, Innodia Inc. has no internal research capabilities...
...targets that will allow the company to "broaden the way in which diabetes is attacked." Innodia's...
...that Innodia's strategy is to partner or out-license each of its programs after Phase IIb. Innodia...
BioCentury | Jul 18, 2005
Emerging Company Profile

Corporate Profile

Innodia Inc. Laval, Quebec Technology: Small molecules to treat and prevent Type II diabetes Disease focus: Metabolic Clinical status: Phase Ib Founded: 2002 by Claude Vezeau and Francois Mongrain University collaborators: McGill University , Bar-Ilan University,...
Items per page:
1 - 10 of 15
BioCentury | Jul 21, 2008
Company News

Bellus Health, Innodia deal

...acquired Innodia for C$1.3 million (US$1.3 million) in stock. The purchase includes the assumption of Innodia's...
...II diabetes, with interim data expected in 1H09. Bellus Health Inc. (TSX:BLU; NASDAQ:BLUS), Laval, Quebec Innodia Inc....
BioCentury | Mar 26, 2007
Product Development

Targeting obesity

...blocks NPY5 receptor (4) . The mechanisms for Manhattan Pharmaceuticals' natural hormone oleoyl-esterone and Innodia's...
BioCentury | Mar 26, 2007
Product Development

Metabolic Milestones

...up the body's energy expenditure without a concomitant increase in appetite. In that camp is Innodia Inc....
...of fat into triglycerides. While Adyvia was initially developed for Type II diabetes, Vezeau said Innodia...
...and lipid profile. While the exact mechanism of Adyvia has yet to be fully elucidated, Innodia...
BioCentury | Mar 26, 2007
Product Development

Reaching proof of concept

...data 07 (A) GlaxoSmithKline/ Kissei Sergliflozin (869682, KGT-1251) Sodium-glucose cotransporter 2 (SGLT2) inhibitor SGLT2 NA Innodia...
BioCentury | Mar 12, 2007
Company News

Innodia scientific advisory board update

Innodia Inc. , Laval, Quebec Business: Endocrine Appointed: David York, director of the Center for Advanced Nutrition at Utah State University; and Robert Zamboni, former VP at Merck & Co. Inc. WIR Staff...
BioCentury | Dec 11, 2006
Clinical News

Adyvia: Phase IIa started

...Innodia began a double-blind, placebo-controlled, Canadian Phase IIa trial in 100 patients. Innodia Inc. , Laval, Quebec...
BioCentury | Dec 4, 2006
Company News

Innodia management update

Innodia Inc. , Laval, Quebec Business: Endocrine Hired: Nigel Levens as CSO, formerly head of biology at Biovitrum AG WIR Staff...
BioCentury | Nov 22, 2006
Company News

Innodia names Levens CSO

...Diabetes and obesity company Innodia (Laval, Quebec) hired Nigel Levens as CSO, a newly created position...
BioCentury | Jul 18, 2005
Emerging Company Profile

Innodia: Surrounding diabetes

...In a slight twist on the typical NRDO business model, Innodia Inc. has no internal research capabilities...
...targets that will allow the company to "broaden the way in which diabetes is attacked." Innodia's...
...that Innodia's strategy is to partner or out-license each of its programs after Phase IIb. Innodia...
BioCentury | Jul 18, 2005
Emerging Company Profile

Corporate Profile

Innodia Inc. Laval, Quebec Technology: Small molecules to treat and prevent Type II diabetes Disease focus: Metabolic Clinical status: Phase Ib Founded: 2002 by Claude Vezeau and Francois Mongrain University collaborators: McGill University , Bar-Ilan University,...
Items per page:
1 - 10 of 15